Previous Close | 1,446.50 |
Open | 1,450.00 |
Bid | 1,452.15 x 0 |
Ask | 1,452.15 x 0 |
Day's Range | 1,439.00 - 1,455.35 |
52 Week Range | 834.90 - 1,592.55 |
Volume | |
Avg. Volume | 36,110 |
Market Cap | 844.424B |
Beta (5Y Monthly) | 0.53 |
PE Ratio (TTM) | 24.17 |
EPS (TTM) | 60.10 |
Earnings Date | Nov 07, 2024 - Nov 11, 2024 |
Forward Dividend & Yield | 4.50 (0.31%) |
Ex-Dividend Date | Feb 20, 2024 |
1y Target Est | 762.03 |
Aurobindo Pharma (NS:ARBN) has outperformed expectations in the fourth quarter of FY24, with both sales and EBITDA showing significant year-over-year growth. Sales increased by 17%, while EBITDA surged by an impressive 68%, surpassing both Goldman Sachs (NYSE:GS)' projections and those of the broader market. The EBITDA margin also exceeded forecasts, reaching 22.3%, which is 101 basis points higher than Goldman Sachs' estimate.